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A  toxicological  evaluation  of a  umami  ﬂavour  compound,  2-(((3-(2,3-dimethoxyphenyl)-1H-1,2,4-
triazol-5-yl)thio)methyl)pyridine  (S3643;  CAS 902136-79-2),  was  completed  for  the  purpose  of  assessing
its  safety  for use in  food  and beverage  applications.  S3643  undergoes  extensive  oxidative  metabolism
in  vitro  with  rat microsomes  producing  the S3643-sulfoxide  and  4′-hydroxy-S3643  as  the  major  metabo-
lites.  In incubations  with  human  microsomes,  the  O-demethyl-S3643  and S3643-sulfoxide  were  producedeywords:
mami  ﬂavour
3643
EMA GRAS
ubchronic toxicological evaluation
enetic toxicological evaluation
as  the  major  metabolites.  In pharmacokinetic  studies  in rats,  the  S3643-sulfoxide  represents  the dom-
inant  biotransformation  product.  S3643  was not  found  to be mutagenic  or  clastogenic  in vitro,  and  did
not  induce  micronuclei  in  CHO-WBL cells.  In subchronic  oral  toxicity  studies  in  rats,  the no-observed-
adverse-effect-level  (NOAEL)  for S3643  was  100  mg/kg  bw/day  (highest  dose  tested)  when administered
in  the  diet  for 90  consecutive  days.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Umami, the savory taste of the amino acid l-glutamate, is one
f the ﬁve basic taste qualities detected by humans. Monosodium
lutamate (MSG) is the prototypical umami  substance commonly
dded to many food and beverage compositions, often at con-
entrations of 0.1–0.8% (1000–8000 ppm) by weight, to improve
heir overall fullness and savory ﬂavour. In addition, it is known
hat naturally occurring purine ribonucleotides such as inosine-5′-
onophosphate and guanosine-5′-monophosphate which elicit no
mami  taste on their own, can synergistically potentiate the umami
aste of glutamate, thereby requiring less MSG  for a given ﬂavour-
Abbreviations: amu, atomic mass unit; AUC, area under the curve; CL, plasma
learance; Cmax, peak plasma concentration; CYP, cytochrome P450; FDA, Food
nd Drug Administration; FEMA, Flavour and Extract Manufacturers Association of
he United States; FL-no, FLAVIS number; GLP, Good Laboratory Practices; GMP,
ood Manufacturing Practices; GPCR, G-protein-coupled receptor; GRAS, gener-
lly recognized as safe; HPBL, human peripheral blood lymphocytes; LC/MS, liquid
hromatography with mass spectrometry; MC,  methylcellulose; MSG, monosodium
lutamate; NOAEL, no-observed-adverse-effect-level; NOEL, no-observed-effect-
evel; OECD, Organization for Economic Cooperation and Development; PK,
harmacokinetics; RCG, Relative Cell Growth; RMI, Relative Mitotic Index; t1/2,
alf-life; Tmax, time to reach Cmax; TK, toxicokinetics; Vss, volume of distribution
t  steady-state.
∗ Corresponding author.
E-mail address: amy.arthur@senomyx.com (A.J. Arthur).
1 Current address: Crinetics Pharmaceuticals, Inc., 6197 Cornerstone Ct, San Diego,
A  92121, United States.
ttp://dx.doi.org/10.1016/j.toxrep.2016.05.002
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ing application. While these purine ribonucleotides can be present
along with glutamate in certain food ingredients such as autolyzed
yeast extracts, they are expensive to either isolate from natural
sources or to synthesize. Until recently, little progress has been
made in identifying high potency artiﬁcial substitutes for MSG  or
potentiators of the effectiveness of naturally occurring glutamate
already present in food products.
Umami  substances are detected by a speciﬁc subset of
taste receptor cells localized in the taste bud and character-
ized by the expression of members of the hTAS1R family of
class C G-protein-coupled receptors (GPCRs), which are dis-
tantly related to calcium sensing receptor, V2R pheromone
receptors, and metabotropic glutamate receptors [13,14,31]. Co-
expression of both hTAS1R1 and hTAS1R3 in heterologous cells
results in a functional, heteromeric receptor which is highly
selective for umami  stimuli, responding only to glutamate, aspar-
tate, and l-2-amino-4-phosphonobutrate. Most importantly, the
glutamate-induced activity of the hTAS1R1/hTAS1R3 heterodimer
is also strongly potentiated by inosine-5′-monophosphate and
guanosine-5′-monophosphate, thereby proving further support
for its identity as the human receptor for umami  taste. This
functional assay for hTAS1R1/hTAS1R3 has been adapted for high-
throughput screening of natural extract and synthetic libraries
leading to the discovery of several classes of novel umami
agonists including a series of highly potent oxalamide com-
pounds [24–26]. Several of these oxalamide umami  agonists
have been evaluated for potential genotoxicity and in vivo
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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oxicity in rodents and have received regulatory approval
s ﬂavouring agents including N1-(2,4-dimethoxybenzyl)-N2-(2-
pyridin-2-yl)ethyl)oxalamide (S336, CAS 745047-53-4, FEMA
233, FL-no. 16.099, Savorymyx® UM33). S336 has worldwide reg-
latory approval for use as a ﬂavour compound and has been used
o reduce or replace MSG  in a variety of products including sauces,
rozen foods, cooking aids and snack foods.
More recently, researchers at Senomyx, Inc. have
eported a series of novel 3-aryl-5-alkylthio-1,2,4-triazoles,
ncluding 2-(((3-(2,3-dimethoxyphenyl)-1H-1,2,4-triazol-5-
l)thio)methyl)pyridine (S3643; CAS 902136-79-2), which are also
otent agonists of the human umami  receptor [27,28]. Like several
f the aforementioned oxalamides, S3643 can provide an umami
avour effect in product applications equivalent to that of MSG
t a 1000-fold lower concentration. The structure of S3643 along
ith representative analogs from the oxalamide series is shown in
ig. 1.
S3643 was reviewed by the Expert Panel of the Flavour and
xtract Manufacturers Association of the United States (FEMA) and
etermined to be generally recognized as safe (GRAS) under condi-
ions of intended use as a ﬂavour ingredient [1,8,17] and therefore
s available for use in human food in the United States as a “FEMA
RAS” ﬂavour ingredient. S3643 was assigned FEMA GRAS Number
798 in 2014 [1].
The purpose of this publication is to summarize the results
btained from in vitro metabolism and in vivo pharmacokinetic
PK) studies, general toxicology studies in rodents, and genotoxicity
tudies conducted with S3643. Additional supporting data obtained
n these studies with S3643 is included in a Supplementary Data
ection in the online publication.
. Materials and methods
The batch of S3643 used for the in vitro/in vivo metabolism,
n vivo pharmacokinetic, and 28-day range-ﬁnding toxicity studies
Lot no. BP110707, purity >99%, mp  114.7–115.5 ◦C), was syn-
hesized at Ajinomoto Co., Inc., Kawasaki-Shi, Japan using the
rocedure described in US Patent No. 8,784,782 B2 and 8,968,708
2 [27,28]. The batch of S3643 used for the in vitro genotoxicity
nd 90-day subchronic toxicity studies (Lot no. 60287-12-001-
, purity >98.5%, mp  114.7–115.3 ◦C) was synthesized at Ricerca
iosciences, LLC, Concord, OH using a slight modiﬁcation of the
ame synthetic method but also prepared in conformance with
ood Manufacturing Practices (GMPs) as described in the ICH GMP
uidelines for APIs [10]. Both batches of S3643 used for these
tudies gave identical 1H NMR  (400 MHz, d6-DMSO), 13C NMR
100 MHz, d6-DMSO), FT-IR (KBr pellet), and mass spectral data.
All genetic toxicology studies were conducted in compliance
ith the United States Food and Drug Administration (FDA) Good
aboratory Practices (GLP) regulations 21 CFR Part 58 [6] and OECD
uidelines [22]. The experimental design for these studies followed
he OECD Guidelines for the Testing of Chemicals – 471, 473, and
87 [20,21,23]. The 28-day dose-range ﬁnding studies and 90-day
oxicology studies in rats were conducted in compliance with FDA
uidelines [7] Toxicological Principles for the Safety of Food Ingre-
ients; the 90-day subchronic toxicology study was also conducted
n compliance with GLP regulations, 21 CFR Part 58.
The receptor panel proﬁling and cytochrome P450 (CYP)
nhibition assays on S3643 were conducted at MDS  Pharma
ervices-Taiwan Ltd, Taipei, Taiwan. The in vitro microsomal
etabolism studies on S3643 were carried out by PharmOptima,
ortage, MI.  The microsomal metabolism studies utilized male and
emale rat liver microsomes (Lot no. 1010122 and 0710104, respec-
ively) and mixed gender human microsomes (Lot no. 087K1440)
btained from XenoTech, Lenexa, KS. The hERG channel inhibition Reports 3 (2016) 501–512
assay on S3643 was  carried out by Aviva Biosciences, San Diego, CA.
Additional in vitro microsomal metabolism studies, as well as phar-
macokinetic (PK) and in vivo metabolism studies on S3643 in rats
were conducted at Senomyx, San Diego, CA. The analytical methods
used for the in vitro metabolism, PK and in vivo metabolism studies
can be found in the Supplementary Data section published online.
The in vitro genotoxicity studies for S3643 were conducted at
Nucro-Technics, Scarborough, Ontario, Canada. The strains of S.
typhimurium and E. coli, as well as rat liver S9 (9000 × g super-
natant fraction of liver homogenate from Sprague-Dawley rats
treated with AroclorTM 1254) used in the reverse bacterial muta-
tion assay were obtained from Molecular Toxicology Inc., Boone,
NC. Cultures of human lymphocytes (Lot no. A2544) used for the
chromosome aberration test were obtained from StemCell Tech-
nologies (Vancouver, BC, Canada) and were prepared from blood
collected aseptically from a 20 year old, healthy, non-smoking
donor. Chinese hamster ovary cell line WBL (CHO-WBL) used for
the in vitro micronucleus test was  obtained from Dr. M.D.  Baker,
The Department of Pathobiology, University of Guelph (Guelph,
ON, Canada). Rat liver S9 (9000 × g supernatant fraction of liver
homogenate from Sprague-Dawley rats treated with phenobar-
bital and 5,6-benzoﬂavone) used in the chromosome aberration
and micronucleus tests was obtained from Molecular Toxicology
Inc., Boone, NC. The 28-day and 90-day subchronic toxicity stud-
ies for S3643 were conducted at MPI  Research, Mattawan, WI.  A
description of the study designs is included in the individual study
sections below. Detailed data tables for the genotoxicity, 28-day
range-ﬁnder, and 90-day subchronic toxicity studies can be found
in the Supplementary Data section published online.
3. Results and study designs
3.1. In vitro receptor and cytochrome P450 proﬁling of S3643
In vitro tests were conducted with S3643 to assess whether the
compound interacts with any enzymes or receptors that might
cause adverse or unexpected effects or affect drug metabolism.
Preliminary in vitro screening for potential off-target activity of
S3643 included tests for CYP inhibition, a receptor lead proﬁling
panel (consisting of 68 receptor binding assays for GPCRs, ion chan-
nels, nuclear receptors, transporters), and a hERG inhibition assay.
The preliminary tests for CYP inhibition were performed using
recombinant human enzymes expressed in insect Sf9 cells using
spectroﬂuorimetric substrates [2,18]. All assays were performed at
a concentration of 10 M of S3643. No signiﬁcant responses (≥50%
inhibition or stimulation) were found with S3643 in the lead pro-
ﬁling receptor screen. S3643 did not signiﬁcantly inhibit the hERG
ion channel current (<10%) in an in vitro hERG electrophysiology
(patch clamp) assay [29]. However, S3643 did show signiﬁcant
inhibition of CYP1A2 and 3A4 (72% and 68% inhibition, respec-
tively) at 10 M in the spectroﬂuorimetric assay using recombinant
human enzymes. As a follow up to the results obtained using spec-
troﬂuorimetic substrates, S3643 retested on the same panel of CYP
enzymes utilizing human liver microsomes and CYP-speciﬁc sub-
strates with detection of the CYP-speciﬁc metabolites by LC–MS/MS
[15,30]. None of the CYP isoforms (including CYP1A2 and 3A4) were
inhibited by >43% in the presence of 10 M S3643 in this more
deﬁnitive assay format (i.e., all IC50’s >10 M).  The results from the
CYP inhibition studies are summarized in Table 1.
3.2. Absorption, distribution, metabolism, excretionThe in vitro metabolism of S3643 was studied using rat and
human liver microsomes. A study of the PK and in vivo metabolism
of S3643 was  carried out in male and female Sprague-Dawley rats.
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Fig. 1. Structures of S3643 and oxalamide umami  agonists.
Table 1
Cytochrome P450 Inhibition by S3643.
CYP Spectroﬂuorimetric assay, human recombinant enzymes, Sf9 cells LC–MS/MS assay in human liver microsomes
Probe Substrate % Inhibition (10 M) Probe Substrate % Inhibition (10 M)
1A2 3-cyano-7-ethoxycoumarin 72% phenacetin 43%
2C9  3-cyano-7-ethoxycoumarin 5% tolbutamide 8%
% S-mephenytoin 13%
3% bufuralol 22%
% midazolam 30%
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Table 2
Major Metabolites of S3643 in Rat and Human Microsomal Incubations (60 min).
Metabolite m/z (M+H) Formula % MS  Peak Areaa RT (min)b
Rat Human
S3643 329.1067 C16H17N4O2S+ 18.4% 54.9% 5.79
M344A 345.1016 C16H17N4O3S+ 18.6% 6.48% 5.46
M344B 345.1016 C16H17N4O3S+ 10.5% 1.82% 4.42
M314A 315.0910 C15H15N4O2S+ 3.26% 2.02% 5.46
M314B 315.0910 C15H15N4O2S+ 2.28% 13.8% 4.26
M330A 331.0859 C15H15N4O3S+ 0.801% 0.824% 4.97
M330B 331.0859 C15H15N4O3S+ 3.39% <1% 4.05
M330C 331.0859 C15H15N4O3S+ <1% <1% 3.18
M330D 331.0859 C15H15N4O3S+ <1% <1% 4.31
M300 301.0754 C14H13N4O2S+ <1% <1% 4.00
a Percent integrated MS peak areas from HESI positive ion Q1 MS scan relative to
integrated MS peak area of S3643 at time = 0.
b Retention time using a Zorbax Eclipse Plus C18 column (50 × 2.1 mm, 1.8 m)2C19  3-cyano-7-ethoxycoumarin 42
2D6  3-cyano-7-ethoxycoumarin −
3A4  7-benzyloxy-4-(triﬂuoromethyl)-coumarin 68
.2.1. In vitro metabolism of S3643
The potential of S3643 to undergo oxidative metabolism was
nvestigated using Sprague-Dawley rat and human liver micro-
omes in order to determine the similarity of the metabolic proﬁle
cross these species. Reference standards were synthesized for
he three potential oxidative metabolites that could be produced
y mono-hydroxylation of the 2,3-dimethoxyphenyl moiety, as
ell as the S3643-sulfoxide, the two mono-O-demethylated S3643
nalogs, and the analogous di-O-demethylated compound. S3643
10 M)  was incubated with mixed gender, pooled rat and human
iver microsomes (0.5 mg/mL) in the presence of NADPH (1.3 mM)
t 37 ◦C for 60 min  prior to quenching the samples with acetonitrile.
ontrol samples included time zero and 60 min  incubations with-
ut NADPH as well as testosterone incubation samples in order to
erify microsome functionality.
Samples were centrifuged to separate the precipitated micro-
omes from the supernatant containing the parent compound and
ts metabolites. The supernatants from the S3643 incubations were
nalyzed by liquid chromatography-mass spectrometry (LC–MS)
sing a Phenomenex Kinetex C18 column (2.6 m,  50 × 2.1 mm)
ith a 1.0 mM  ammonium acetate and methanol gradient sys-
em, and a Thermo Electron Quantum Access mass spectrometer
sing heated electrospray ionization (HESI). The samples were
canned in the both positive and negative ionization modes for
ommon Phase I transformations including addition of oxygen
+16), mono- and di-O-demethylation (−14 and −28, respectively),
ono-O-demethylation + addition of oxygen (+2), addition of two
xygens (+32), and S-dealkylation (−91). Positive control incuba-
ions with testosterone with and without NADPH were analyzed
n HESI positive ion mode. There was greater than 85% turnover
f testosterone in parallel incubations with microsomes of both
pecies in the presence of NADPH at the 60 min  time point. Sam-
les from a duplicate incubation with rat liver microsomes were
nalyzed by LC-QTOF/MS (Agilent iFunnel 6550A MS  QTOF, posi-
ive mode) equipped with an Agilent 1290 Inﬁnity Binary pump
nd an Agilent 1290 Inﬁnity autosampler using a Zorbax Eclipse
lus C18 column (50 × 2.1 mm,  1.8 m)  with 2.0 mM ammonium
cetate/0.1% formic acid/water and methanol gradient system to
onﬁrm the exact mass of the observed metabolites. Details of the
nalytical methods can be found in the Supplementary Data section.
In the rat and human microsome incubations, roughly 18.4%
nd 54.9% of the parent was remaining at the end of the microso-and 2 mM ammonium acetate/0.1% formic acid/water and methanol gradient sys-
tem.
mal  incubation period, respectively. At the 60 min  time point, nine
potential Phase I metabolites were observed at levels ranging from
<1% to 18.6% of the initial S3643 peak area in both the rat and human
incubations (see Fig. 2 and Table 2). The two major metabolites
observed in the rat microsomal incubations were S3643-sulfoxide
(M344A), and 4′-hydroxy-S3643 (M344B), representing roughly
18.6% and 10.5% of the initial S3643 peak area, respectively. The
position of the hydroxyl group in metabolite M344B was conﬁrmed
by direct comparison to synthetic samples of the three possible
hydroxy-2,3-dimethyoxyphenyl regioisomers (see Supplemental
Material). The two major metabolites observed in the human
microsomal incubations were an O-desmethyl-S3643 (M314B) and
S3643-sulfoxide (M344A), representing roughly 13.8% and 6.48%
of the initial S3643 peak area, respectively. The 4′-hydroxy-S3643
(M344B) seen as a major metabolite in the rat microsomal incu-
bations was  also present in the human microsomal incubations,
but at signiﬁcantly lower concentrations (1.82% of the initial S3643
peak area). Likewise, the O-desmethyl-S3643 (M314B) seen as
a major metabolite in the human microsomal incubations was
also seen as a minor metabolite in the rat incubations (2.28% of
the initial S3643 peak area). Other metabolites observed in both
the rat and human microsomal incubations include a second O-
desmethyl-S3643 (M314A), a di-O-desmethyl-S3643 (M300), and
504 D.S. Karanewsky et al. / Toxicology Reports 3 (2016) 501–512
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sFig. 2. Structures of S3643
wo O-desmethyl-S3643 sulfoxides (M330A and M330B). A third
etabolite (M330C) with molecular weight of 330 amu  appears
o be an O-desmethyl-S3643 which has been hydroxylated on the
henyl appendage. A fourth metabolite (M330D) with a molecular
eight of 330 amu  appears to be the result of addition of an oxy-
en atom to the pyridyl ring. Both M330C and M330D represent less
han 1% of the initial S3643 initial peak area in the rat microsomal
ncubations. The structures of M344A, M344B, M314A, M314B, and
300 were conﬁrmed by direct comparison to synthetic samples by
C–MS/MS. The structures of M330A, M330B, M330C, and M330D
re based on their exact masses and MS  fragmentation patterns,
ut have not been conﬁrmed by comparison to synthetic samples
see Supplemental Material).
.2.2. Pharmacokinetics of S3643 in rats
The PK parameters and oral bioavailability of S3643 in plasma
as evaluated following either a single intravenous or oral admin-
stration in male and female Sprague-Dawley rats. For intravenous
dministration, 4 male and 4 female Sprague-Dawley rats were
olus injected with S3643 at 1 mg/kg bw in 10% ethanol in 20 mM
otassium phosphate buffer (pH 7.4). Blood samples were col-
ected from a jugular catheter at approximately 0, 2, 5, 10, 30 min,
, 2, 4, and 8 h post-dose. For oral administration, 4 male and
 female Sprague-Dawley rats per group were given a single
ose of S3643 at either 10, 30, or 100 mg/kg bw in 1% methyl-
ellulose (MC) by oral gavage. Blood samples were taken from
 jugular catheter at approximately 0, 15, 30 min, 1, 2, 4, 8,
nd 24 h post-dose. Proteins from plasma samples (25 L) were
recipitated by addition of acetonitrile (75 L) containing an
nternal standard [2-(((3-(2,4-dimethylphenyl)-1H-1,2,4-triazol-
-yl)thio)methyl)pyridine; S9767, 25 ng/mL], centrifuged, and
0 L of the resulting supernatant was mixed with deionized
ater (100 L). The resulting solutions were analyzed for S3643
y LC–MS/MS using a Waters SunFire C18 column (50 × 2.1 mm,
.5 m)  with 0.1% formic acid/water and acetonitrile gradient sys-
em and a API 3200 Q-Trap mass spectrometer operated in positive
onization mode equipped with an Agilent 1100 binary pump with
 CTC PAL injector. The parent compound and internal standard
IS) were detected using a source that was conﬁgured with tur-
oionspray ionization in the positive mode using multiple-reaction
onitoring (MRM)  of mass transition pairs at m/z  of 329.1/206.1
S3643) and 297.1/174.1 (IS, S9767) amu. Details of the analyti-
al methods can be found in the Supplementary Data section. Test
rticle formulations prepared for this study were analyzed for con-
entration by HPLC-UV (265 nm). The PK parameters for S3643 are
hown in Table 3.r microsomal metabolites.
S3643 was rapidly eliminated after intravenous administration
in both male and female rats with mean terminal half-lives (t1/2)
of 0.19 and 0.16 h, respectively. Mean plasma clearance (CL) in rats
averaged 5.97 mL/min/kg for males (10.8% of hepatic blood ﬂow,
[3]) and 8.03 mL/min/kg for females (14.5% of hepatic blood ﬂow),
and the volume of distribution at steady-state (Vss) averaged 337
and 325 mL/kg (50.4% and 48.6% of total body water volume) for
males and females, respectively.
For oral administration, the mean values for the t1/2 of S3643
in plasma ranged from 0.80 to 1.66 h in male rats and 0.89–1.66 h
in female rats. Both mean AUClast and mean Cmax increased with
increasing oral dose, but the increase was not dose proportional
in either male or female rats. For male rats, the mean Cmax for
an oral dose of 10, 30, and 100 mg/kg bw was  32.51, 50.88, and
78.27 g/mL, respectively; the mean AUClast for these doses was
26.65, 80.33, and 183.30 g·h/mL, respectively. For female rats, the
mean Cmax for an oral dose of 10, 30, and 100 mg/kg bw was 14.89,
45.38, and 98.91 g/mL, respectively; the mean AUClast for these
doses was 14.23, 73.51, and 239.30 g·h/mL, respectively.
The ratio of female/male exposure to S3643 (Cmax and AUClast)
in plasma was  used for comparison of gender differences. For intra-
venous administration, the female/male ratios of mean AUClast and
Cmax were 0.76 and 0.91, respectively. For oral administration, the
female/male ratios of mean AUClast ranged from 0.53 to 1.31 and
the female/male ratio of mean Cmax ranged from 0.46 to 1.26. The
absolute bioavailability (%F) ranged from 67.4% to 116.1% in female
rats and 65.7% to 96.0% in male rats.
3.2.3. In vivo metabolism of S3643 in rats
The in vivo metabolism of S3643 was  evaluated following a sin-
gle oral administration in male and female Sprague-Dawley rats. A
group of 4 male and 4 female Sprague-Dawley rats was  admin-
istered 100 mg/kg bw of S3643 in 1% MC by oral gavage. Blood
samples were collected from a jugular catheter at approximately
15, 30 min, 1, 2, 4, 8, and 24 h post-dose. Plasma samples (10 L)
from each animal was  pooled together by each time point. Proteins
from the combined plasma samples (80 L) were precipitated by
addition of acetonitrile (240 L) containing an internal standard
(S9767, 25 ng/mL), centrifuged, and 50 L of the resulting super-
natant was  mixed with deionized water (100 L). The resulting
solutions were analyzed for the parent compound and metabolites
by LC-QTOF/MS (Agilent iFunnel 6550A MS  QTOF, positive mode)
equipped with an Agilent 1290 Inﬁnity Binary pump and an Agilent
1290 Inﬁnity autosampler using a Zorbax Eclipse Plus C18 column
(50 × 2.1 mm,  1.8 m)  with 2.0 mM  ammonium acetate/0.1% formic
acid/water and methanol gradient system. Details of the analytical
methods can be found in the Supplementary Data section.
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Table  3
Pharmacokinetics of S3643 in Male (n = 4) and Female (n = 4) Sprague-Dawley Rats.
Route Dose (mg/kg bw) Sex Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-last (ng·h/mL) AUC0-last/dose (ng·h/mL/mg/kg) % F
iv 1.0 M 10870 ± 1870 0.03 0.19 2790 ± 187 2790 –
F  9840 ± 1880 0.03 0.16 2110 ± 353 2110 –
oral  gavage 10 M 32510 ± 7710 0.25 0.80 26650 ± 7040 2665 95.5%
F  14890 ± 7870 0.25 0.89 14230 ± 8860 1423 67.4%
30 M  50880 ± 10800 0.44 0.97 80330 ± 29900 2678 96.0%
F  45380 ± 5030 0.25 1.14 73510 ± 33760 2450 116.1%
100 M  78270 ± 9520 0.31 1.66 183300 ± 42930 1833 65.7%
F  98910 ± 19350 0.38 1.66 239300 ± 119400 2393 113.4%
Male rat: CL = 5.97 mL/min/kg; Vss = 337 mL/kg Female rat: CL = 8.03 mL/min/kg; Vss = 325 mL/kg.
CL  = clearance; Vss = steady-state volume of distribution; % F = bioavailability.
Table 4
S3643 and Metabolites Observed at 1 h in Rat Plasma (Males and Females Combined, n = 8).
Compound m/z (positive) Formula Peak Area (×106) % Peak Area RT (min)
S3643 329.1069 C16H17N4O2S+ 69.9 55.52 5.80
M344A 345.1016 C16H17N4O3S+ 54.6 43.39 5.48
M344B 345.1016 C16H17N4O3S+ 0.119 0.09 4.43
M314A 315.0910 C15H15N4O2S+ 0.488 0.39 5.46
M314B 315.0910 C15H15N4O2S+ 0.0288 0.02 4.26
M330A 331.0859 C15H15N4O3S+ 0.0287 0.02 4.97
M330B 331.0859 C15H15N4O3S+ 0.0165 0.01 4.06
M394 395.0478 C15H15N4O5S2+ 0.570 0.45 3.22
M520 521.1337 C22H25N4O9S+ 0.121 0.10 2.74
M300 301.0754 C14H13N4O2S+ (trace) <0.01 4.00
athwa
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bFig. 3. Metabolic p
Seven Phase I metabolites and two Phase II metabolites of
3643 were observed in the rat plasma samples. The MS  extracted
on chromatogram (EIC) peak areas for S3643 and its metabo-
ites observed at the 1 h time point are shown in Table 4. The
hase I metabolic biotransformation of S3643 involved oxidation
f the thioether, demethylation, and hydroxylation of the phenyl
ppendage. The sulfoxide (M344A) of S3643 was  the dominant
iotransformation. Both mono-O-desmethyl-S3643 metabolitesy of S3643 in rats.
(M314A and M314B) and 4′-hydroxy-S3643 (M344B) were also
observed in the rat plasma, but at much lower concentrations.
The structures of M344A, M344B, M314A, and M314B were con-
ﬁrmed by direct comparison to synthetic samples by LC–MS/MS. In
addition to traces of the other Phase I metabolites observed previ-
ously in the in vitro microsomal metabolism study (M330A, M330B,
M300), a desmethyl, O-sulfate (M394) and glucuronide (M520)
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tig. 4. Mean plasma concentrations of S3643, M344A, M314A and M314B after
ral  administration of S3643 (100 mg/kg) to Sprague-Dawley rats (male and female
ombined, n = 8).
ere also observed in the rat plasma samples. The metabolic path-
ay of S3643 in rats is shown in Fig. 3.
The mean combined AUClast of sulfoxide M344A was approx-
mately 2.17-fold of the parent compound S3643 (see Table 5
nd Fig. 4). The mean combined Cmax of sulfoxide M344A was
4.2 g/mL (128.5 M)  versus 86.0 g/mL (262 M)  for S3643.
oth S3643 and its sulfoxide M344A have t1/2 in the range of
.56-3.05 h. The Cmax of both O-desmethyl metabolites M314A and
314B was signiﬁcantly lower (0.090 and 0.244 g/mL, respec-
ively). It is worth noting that metabolite M314B appears to have
 signiﬁcantly shorter t1/2 than its regioisomer M314A and their
ystemic exposures based on AUClast are similar despite the higher
max for M314B. This may  be due in part to the rapid conversion of
314B to the corresponding O-sulfate M394. Although the actual
oncentrations of the desmethyl, O-sulfate (M394) and glucuronide
M520) could not be determined due to unavailability of synthetic
amples, the MS  EIC peak areas suggest that they are present in con-
entrations comparable to those of the O-desmethyl metabolites
314A and M314B. Overall, the results indicate that the sulfoxide
M344A) of S3643 represents the dominant biotransformation in
ats.
.3. Genotoxicity and mutagenicity studies
S3643 was evaluated for its genotoxic potential in vitro through
tandard (5-strain) Ames, chromosome aberration, and micronu-
leus tests (see Table 6). All genetic toxicology studies were
onducted in compliance with the FDA GLP regulations 21 CFR
art 58 (2006) and OECD guidelines (1998). The data tables for the
enotoxicity studies can be found in the Supplemental Material.
.3.1. Bacterial reverse mutation test (5-Strain Ames)
S3643 was evaluated for the potential to induce point or frame
hift mutations in S. typhimurium strains TA98, TA100, TA1535,
A1537 and E. coli strain WP2  uvrA in the presence and absence
f metabolic activation with rat liver S9 from rats induced with
roclorTM 1254. The assay was designed to meet the current OECD
uideline for Testing of Chemicals No. 471, Bacterial Reverse Muta-
ion Test [20].
In the plate incorporation assay, both in the presence and
bsence of S9, the maximum concentration of S3643 investi-
ated for the S. typhimurium strains was 2000 g/plate. In the
reincubation experiment in the absence of S9, the maximum con-
entration of S3643 utilized for the S. typhimurium strains was also
000 g/plate. Due to increased toxicity in the presence of S9, the
aximum concentration of S3643 investigated in the preincuba-
ion assay for the S. typhimurium strains was 1000 g/plate. For
he E. coli strain in both the plate incorporation and preincubation Reports 3 (2016) 501–512
assays, the maximum concentration tested was  5000 g/plate both
in the presence and absence of S9. Once plated and at the end of
the incubation period, slight and moderate precipitate was  visible
at 2000 and 5000 g/plate, respectively. Therefore at these con-
centrations, the test article was  evaluated at the limit of solubility
in the test system. Slight toxicity was  observed for S. typhimurium
strains as evident by a reduction in colony counts at the higher
concentrations when compared to the concurrent negative con-
trols. However, a normal lawn was observed for all conditions and
toxicity was  not observed for the E. coli strain in all conditions. For
all strains and conditions, a minimum of 5 concentrations were
analyzable for mutagenicity.
For the plate incorporation test, with or without metabolic acti-
vation, S3643 did not produce any statistically signiﬁcant increases
in revertants over the concurrent negative controls. The preincuba-
tion test conﬁrmed the negative results of the plate incorporation
test as S3643 did not produce any increases in revertants over
the concurrent negative controls. The negative controls for each
tester strain were within the historical negative control data. All
concurrent positive controls induced signiﬁcant increase (p < 0.01,
t-test) in colony counts (at least 3.4-fold) when compared to the
corresponding negative controls and were at levels similar to the
historical positive control data. Thus, it was concluded that S3643
was not mutagenic to S. typhimurium strains TA98, TA100, TA1535,
TA1537 and E. coli strain, WP2  uvrA, in the absence and presence of
metabolic activation.
3.3.2. In vitro chromosome aberration test
S3643 was investigated for its potential to induce structural
and numerical chromosome aberrations in mammalian cells, both
in the presence and absence of a supplemental liver fraction (S9)
from rats treated with phenobarbital and 5,6-benzoﬂavone. The
experimental design followed the OECD Guideline for the Testing
of Chemicals No. 473, In Vitro Mammalian Chromosome Aberration
Test [21]. A preliminary toxicity test was  performed to establish
the dose range for testing in the cytogenetic test. In the chro-
mosome aberration assay, human peripheral blood lymphocytes
(HPBL) were treated for 3 and 20 h in the non-activated test system
and for 3 h in the S9-activated test system. Solvent and positive con-
trol (mitomycin C, −S9; cyclophosphamide, +S9) cultures were also
included. For all conditions, cultures were harvested approximately
20–21 h after initiation of treatment. Approximately 3 h prior to
harvesting, colchicine was  added to the cultures at 0.1 g/mL to
arrest cells in metaphase.
Test article precipitate was  only observed in the test system for
20-h exposure at the highest concentration of 500 g/mL. For the
3-h exposure experiment without S9 the concentrations 63, 130,
250 and 500 g/mL yielded Relative Cell Growth (RCG) of 100, 93,
99 and 83% and Relative Mitotic Index (RMI) of 89, 94, 64 and 42%,
respectively. For 20-h exposure without S9 the concentrations 63,
130, 250 and 500 g/mL, yielded RCGs of 101, 98, 86 and 51%. The
lowest three concentrations yielded RMIs of 87, 62 and 27%, respec-
tively. The highest concentration was not analyzable for RMI  due
to toxicity. For the 3-h exposure experiment with S9 the concen-
trations 31, 63, 130, and 250 g/mL yielded RCGs of 94, 85, 73 and
78% and RMIs of 113, 93, 76 and 60%, respectively. All conditions
were tested at the limit of test article toxicity evaluated by RCG and
RMI levels.
Under these test conditions, no structural or numerical chro-
mosome aberrations were observed in the S3643-treated cultures
beyond those seen in the concurrent solvent controls. All concur-
rent positive controls induced signiﬁcant numbers (p < 0.001) of
cells with chromosome aberrations. Based on the ﬁndings of this
study, S3643 was  concluded to be negative for the induction of
structural and numerical chromosome aberrations in both non-
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Table  5
S3643 and Metabolites M344A, M314A, and M314B Observed from 0.25–24 h in Rat Plasma (Males and Females Combined, n = 8).
Cmpd Time (h) AUC (ng·h/mL) Cmax (ng/mL) Tmax (h) t1/2 (h)
0.25 0.50 1.0 2.0 4.0 8.0 24.0
Concentration (ng/mL)
S3643 86022.2 81446.8 55905.2 29188.1 14074.8 4832 63 228807.5 86022.2 0.25 2.56
M344A 12639.1 24340.5 36905.6 43577.9 44203.7 25558.1 529.5 497761.5 44203.7 4.00 3.05
M314A 89.6 50.1 30.1 14.8 23 14.4 0 183.9 89.6 0.25 3.67
M314B  243.9 156.1 15.1 3.6 2.5 2.3 0 148.3 243.9 0.25 0.69
Table 6
Summary of Genotoxicity Studies Conducted on S3643.
End-Point Test System Concentration/Dose Result
Reverse mutation (in vitro) S. typhimurium strains TA98, TA100,
TA1535, TA1537 and E. coli strain
WP2  uvrA
S. typhimurium strains: Negative
130–2000 g/plate, plate incorporation,
±S9a
130–2000 g/plate, preincubation, −S9
63–1000 g/plate, preincubation, +S9a
E. coli strain WP2  uvrA:
250–5000 g/plate, plate incorporation
and pre-incubation, ±S9a
Chromosome aberration (in vitro) Primary human lymphocytes 130–500 g/mL, 3 h exposure, −S9 Negative
63–250 g/mL, 3 h exposure, +S9b
63–250 g/mL, 20 h exposure, −S9
Micronucleus formation (in vitro) Chinese hamster ovary cells
(CHO-WBL)
100–300 g/mL, 3 h exposure, −S9 Negative
50–200 g/mL, 3 h exposure, +S9b
16–63 g/mL, 19 h exposure, −S9
clor-1
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ta S9 from rat liver homogenate from male Sprague-Dawley rats treated with Aro
b S9 from rat liver homogenate from male Sprague-Dawley rats treated with phe
ctivated and S9-activated test systems in the in vitro mammalian
hromosome aberration test using HPBL.
.3.3. In vitro micronucleus test
The purpose of this study was to evaluate the genotoxic (clas-
ogenic/aneugenic) potential of S3643 as measured by its ability
o induce micronuclei in Chinese hamster ovary cells (CHO-WBL)
n both the absence and presence of liver preparations (S9 mix)
rom rats treated with phenobarbital and 5,6-benzoﬂavone. The
xperimental design followed the OECD Guideline for the Testing
f Chemicals – 487, In Vitro Mammalian Cell Micronucleus Test [23].
Cultures of CHO-WBL cells were exposed to varying concentra-
ions of S3643 under three different conditions: (1) a 3-h exposure
n the absence of S9 metabolic activation; (2) a 3-h exposure
n the presence of S9; and (3) a 19-h exposure in the absence
f S9 activation. Solvent and positive control (colchicine, −S9;
yclophosphamide, +S9) cultures were also included. Cytochalasin
 at 3 g/mL was present in the medium after the short-term expo-
ure to S3643 and during the extended exposure in its entirety.
ells were harvested approximately 19–21 h (i.e., approximately
.5 × the normal cell cycle length) and two thousand binucleated
ells per concentration (one thousand binucleated cells per culture;
wo cultures per concentration) were examined. All conditions
ere tested near the limit of test article toxicity evaluated by
ytokinesis-Block Proliferation Index (CBPI) levels.
Test article precipitate was observed in the test system only
t the highest exposure concentration of 600 g/mL. Since this
oncentration was toxic to the cells and not harvested, all ana-
yzable concentrations of S3643 were entirely soluble in the test
ystem. For the 3-h exposure experiment without S9, the concen-
rations 100, 200, 300, and 450 g/mL yielded 1, 0, 25 and 93% of
ells in cytostasis, respectively; concentrations of 0, 100, 200 and
00 g/mL were analyzed for micronuclei. For the 19-h exposure
ithout S9, the concentrations 16, 31, 63, 80 and 130 g/mL yielded
0, 22, 50, 87 and 93% cells in cytostasis, respectively; concentra-
ions of 0, 16, 31 and 63 g/mL were analyzed for micronuclei. For
he 3-h exposure experiment with S9, the concentrations 50, 100,254.
bital/5,6-benzoﬂavone.
200 and 300 g/mL yielded −1, −2, 29 and 91% cells in cytosta-
sis, respectively; concentrations of 0, 50, 100 and 200 g/mL were
analyzed for micronuclei.
For all conditions, there was no signiﬁcant increase in micronu-
clei (p > 0.01) observed in the S3643-treated cultures beyond those
seen in the concurrent solvent controls. All positive controls
induced signiﬁcant numbers (p < 0.0001) of cells with micronu-
clei over the concurrent solvent controls. It was  concluded that
exposure to S3643 did not induce micronuclei in cultured Chinese
hamster ovary cells under the conditions of the test.
3.4. In vivo toxicological studies
S3643 was  evaluated in 28-day dose-range ﬁnding and 90-day
subchronic toxicology studies in rats in compliance with the FDA
guidelines [7] Toxicological Principles for the Safety of Food Ingre-
dients (see Table 7). Summary data tables for the 28 and 90-day
toxicology studies for S3643 can be found in the Supplemental
Material.
3.4.1. 28-day dose-range ﬁnding toxicity study
The purpose of this study was  to evaluate the potential systemic
toxicity of S3643 in rats after dietary administration for 28 days
in order to select doses for the 90-day subchronic toxicity study
in rats. Three treatment groups of ﬁve male and ﬁve female CD®
[Crl:CD®(SD)] rats (Charles River Laboratories, Portage, MI), were
administered the test article at dose levels of 10, 30, and 100 mg/kg
bw/day. One additional group of ﬁve animals/sex served as the
control and received untreated (vehicle) diet. The test substance
was administered continuously via the diet throughout the 28 day
treatment period. Dietary concentrations (ppm) of S3643 for each
group were adjusted each week based on bodyweight and food
consumption data, in order to achieve constant doses in terms of
mg/kg bw/day. Survival, clinical observations, body weight, food
consumption, clinical chemistry, ophthalmic examinations, organ
weights, and macroscopic evaluations of all animals were used
to assess potential toxicity. Ophthalmoscopic examinations were
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Table 7
Summary of In Vivo Toxicity Studies Conducted on S3643.
Study Species/Gender (N value) Dose Findings
28-day Dose Range
Finding Toxicity Study
Male & Female
Sprague-Dawley Rats
10, 30, 100 mg/kg bw/day (food
ad-mix)
No test-article related
ﬁndings;
NOEL = 100 mg/kg
bw/day
–5  animals/sex/group
90-day Sub-Chronic
Toxicity Study
Male & Female
Sprague-Dawley Rats
10, 30, 100 mg/kg bw/day (food
ad-mix)
Lower body weight
gain in females at
100 mg/kg/day
–20  animals/sex/group No adverse test-article
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tonducted pretest and prior to the terminal necropsy. Blood and
rine samples for clinical pathology evaluations were collected
rom all animals prior to the terminal necropsy. At study termi-
ation, animals were sacriﬁced by carbon dioxide asphyxiation
efore subsequent exsanguination. Necropsy examinations were
erformed, organ weights were recorded, and only the liver was
icroscopically examined for animals treated at 0 and 100 mg/kg
w/day.
Once daily oral administration of S3643 for 28 days was  well
olerated in rats at dose levels up to 100 mg/kg bw/day, the highest
ose tested. There was no test article-related mortality observed
nd all animals survived until scheduled euthanasia. There were
o test article-related clinical signs, or effects seen on ophthalmic
xaminations, hematology parameters, coagulation parameters,
ed blood cell morphology, clinical chemistry parameters, or urine
hemistry parameters during this study. There appeared to be a
light (non-statistically signiﬁcant) decrease in body weight gain in
he female animals receiving the 30 and 100 mg/kg bw/day doses
elative to the control group, which correlated with decreased food
onsumption. This was not observed in any of the male animal
ose groups. There were no test article-related gross observations,
hanges in absolute or relative organ weights, or microscopic ﬁnd-
ngs observed in the liver at study termination. Based on these
esults, the no-observed-effect level (NOEL) was considered to be
00 mg/kg bw/day for both male and female rats.
.4.2. 90-day subchronic toxicity study
The purpose of this study was to evaluate the potential sub-
hronic toxicity and toxicokinetic (TK) proﬁle of the test article,
3643, in rats after dietary administration for 90 days. Compound
as administered in the diet to four groups of twenty male and
wenty female CD® [Crl:CD®(SD)] rats (Charles River Laboratories,
ortage, MI)  at dose levels of 0 (control), 10, 30, and 100 mg/kg
w/day. Additionally, one control group of three animals/sex and
hree treated groups of six animals/sex/group served as toxicoki-
etic (TK) animals and received the vehicle or test article diet in
he same manner as the main study groups at respective dose lev-
ls of 0, 10, 30, and 100 mg/kg bw/day. The test substance was
dministered continuously via the diet throughout the treatment
eriod. Dietary concentrations (ppm) of S3643 for each group were
djusted each week based on bodyweight and food consumption
ata, in order to achieve constant doses in terms of mg/kg bw/day.
t the conclusion of the study, animals were sacriﬁced by carbon
ioxide asphyxiation before subsequent exsanguination.
Survival, clinical observations, body weight gain, food consump-
ion, hematology, clinical chemistry, urinalysis, organ weights,
acroscopic examination, and histopathologic evaluation of ateast 54 tissues were performed to assess potential toxicity (con-
rol and high dose animals only; see Supplementary Data for list
f tissues examined histopathologically). A functional observa-
ional battery (including, but not limited to, evaluation of activity,related ﬁndings;
NOAEL = 100 mg/kg
bw/day
arousal, autonomic and physical function, neuromuscular function,
salvation, and respiration), motor activity assessment, and opthal-
moscopic examinations were conducted pretest and again during
13th week of test article administration for all main study animals.
Samples for hematology and clinical chemistry evaluations were
collected from all the main study animals on Days 14 and 45, and
again prior to termination. Urinalysis and samples for coagulation
evaluations were collected prior to termination only. Blood for TK
analysis was collected from one cohort of 3 animals/sex (control
animals) at 1 h post the start of the dark cycle on Days 7 and 90.
Samples were collected at alternating time points from 2 cohorts
of 3 animals/sex (treated animals) at 1, 3, 6, 12, and 24 h post the
start of the dark cycle on Days 7 and 90. At study termination,
necropsy examinations were performed and organ weights were
recorded for all main study animals and appropriate organ weight
ratios were calculated (relative to body and brain weights). Micro-
scopic examination of ﬁxed hematoxylin and eosin-stained parafﬁn
sections were performed on sections of tissues from the control
and high-dose (100 mg/kg bw/day) groups. Livers were examined
microscopically in all main study males and females at all dose
levels.
Average daily compound consumption for animals given
10 mg/kg bw/day was  10.3 and 10.7 mg/kg bw/day; for 30 mg/kg
bw/day, 30.8 and 30.9 mg/kg bw/day; and for 100 mg/kg bw/day,
104.4 and 102.3 mg/kg bw/day, for males and females, respectively.
Formulation analysis demonstrated that the formulation prepara-
tion method produced homogeneous preparations (RSD < 20%).
Systemic exposure to S3643 was highly variable and appeared
to be independent of sex following dietary administration of S3643
to male and female rats (see Table 8). Individual and mean plasma
concentration data and female to male dose normalized AUC ratios
were not indicative of any consistent gender difference (female to
male exposure ratio ranged from 0.445 to 2.22). Therefore, the TK
parameters were calculated from the combined mean plasma con-
centrations from both the male and female animals. Peak S3643
mean plasma concentrations were achieved by 6 h post the start of
the dark cycle for the low and mid  dose groups and 3 or 12 h post
the start of the dark cycle for the high dose group on Days 7 and 90.
Consistent with results from PK studies in rats, systemic exposure
to S3643 was  relatively high. For example, at 100 mg/kg bw/day,
the combined mean Cmax on Day 90 was 10.40 g/mL (31.7 M),
and the combined mean AUC0-24hr was 184.0 g·h/mL. Systemic
exposure (AUC0–24 h) and Cmax values of S3643 generally increased
with increasing dose in a greater than dose proportional manner
on Day 7 and on Day 90. For example, a 1:2.95:9.55-fold increase
in achieved daily dose resulted in an approximate 1:5.8:21.1-fold
increase in AUC0–24 h and an approximate 1:7.5:22.5-fold increase
in Cmax values on Day 7. Dose normalized systemic exposure
(AUC0–24 h/Dose) appeared to be greater on Day 90 than on Day
7. Dose normalized accumulation ratios ranged from 1.35 to 1.86.
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Table  8
Toxicokinetics of S3643 in Sprague-Dawley Rats (Males and Females Combined, n = 12).
Time Point Nominal Dose
(mg/kg bw)
Actual
Dosea
(mg/kg bw)
Cmax
(ng/mL)
Tmax (hrs) AUC0-24hr
(ng·h/mL)
Cmax/dose
(ng/mL/mg/kg)
AUC0–24 h/dose
(ng·h/mL/mg/kg)
ACUM Ratiob
Day 7 10 8.63 276 6 4960 31.9 574 –
30  25.5 2060 6 29000 80.6 1140 –
100  82.4 6230 12 105000 75.7 1280 –
Day  90 10 10.8 846 6 11500 78.3 1070 1.86
30  32.3 3160 6 50300 98.0 1560 1.37
100  107 10400 3 184000 97.5 1730 1.35
a Actual dose levels were determined using the weekly food consumption values and te
daily  dose achieved for Weeks 1 and 13 (Days 7 and 90) were used in toxicokinetic analy
b ACUM Ratio = AUC0-24hr/dose at Day 90/AUC0-24hr/dose at Day 7.
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Fig. 5. Mean body weights of male Sprague-Dawley rats (n = 20) receiving S3643 for
13  weeks.
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vig. 6. Mean body weights of female Sprague-Dawley rats (n = 20) receiving S3643
or 13 weeks.
Mean body weight among main study females at 100 mg/kg
w/day was statistically signiﬁcantly lower beginning at Week 5
7% lower, p < 0.05) when compared to controls. The lower means
oincided with decreased mean food consumption (6–14% lower,
 < 0.05) and generally persisted during the dosing period. There
ere no corresponding changes in mean body weight or food
onsumption in the main study males at any dose level (see
igs. 5 and 6). These effects were considered test article-related
ut not adverse at these magnitudes.
There were no test article-related effects among hematology
arameters, coagulation times, or clinical chemistry analytes in
ither sex at any dose level. All mean and individual values
ere considered within an acceptable range for biologic and/or
rocedure-related variation despite occasional mean values that
eached statistical signiﬁcance. There were no test article-related
lterations observed among urinalysis parameters in either sex at
ny dose level. There were occasional differences found in urine
olume and speciﬁc gravity that were not considered toxicolog-
cally meaningful due to their sporadic nature and the inherent
ariability of these endpoints.st article concentration in the diet. Individual values were averaged and the average
sis.
There were no test article-related macroscopic changes or tox-
icologically signiﬁcant test article-related organ weight changes
noted at any dose level. Test article-related organ weight changes
consisted of increased liver weights in males at 100 mg/kg bw/day
relative to control animals (absolute liver weight: 12.5% increase,
p > 0.05; liver/body weight: 14.1% increase, p < 0.01; liver/brain
weight: 13.5% increase, p < 0.05). All other statistically signiﬁcant
organ weight changes were considered incidental/spontaneous as
they were non dose-related, were related to body weight changes,
and/or lacked microscopic correlates.
Test article-related microscopic ﬁndings were limited to a min-
imal degree of liver centrilobular hepatocyte hypertrophy in three
males at 100 mg/kg bw/day. This change consisted of a very slight
increase in the size of the hepatocytes around the central vein of
the liver which correlated to increased liver weights observed in
males at this dose level as noted above. A malignant kidney tumor
(amphophilic-vacuolar renal tubule carcinoma) was  present in the
kidneys of one female animal at 10 mg/kg/day. This tumor was
considered incidental, as it occurred in the low dose group, there
were no other renal tubule tumors in other animals, there were no
pre-neoplastic renal lesions such as tubular hyperplasia in other
animals, and thus was viewed to likely to be of spontaneous, possi-
bly familial, origin. A benign uterus (cervix) smooth muscle tumor
(leiomyoma) was  also present in the same animal. This tumor was
also considered incidental, as it occurred in the low dose group,
there were no other uterus tumors in other animals, and there
were no pre-neoplastic uterus lesions in other animals. All other
microscopic observations were considered incidental/spontaneous
as they were typical of rats of this age, similar in incidence across
groups, and/or of low/isolated frequency.
Overall, there were no adverse test article-related effects noted
for any parameter examined. As a result, the no-observed-adverse-
effect-level (NOAEL) following 90 days of dietary administration
was 100 mg/kg bw/day, the highest dose level tested, in male and
female rats.
4. Discussion and conclusions
S3643 is a member of a novel series of substituted 1,2,4-
triazole agonists of the human umami  receptor hTAS1R1/hTAS1R3,
which differs from previously reported oxalamide-based umami
agonists mainly by the replacement of the oxalamide moiety
by a 1,2,4-triazole ring. In CYP inhibition assays using spec-
troﬂuorimetric substrates with recombinant enzymes, S3643
exhibited signiﬁcant inhibition of CYP1A2 and CYP3A4 (72% and
68% inhibition, respectively) at 10 M.  A structurally related
oxalamide analog, N1-(2,3-dimethoxybenzyl)-N2-(2-(pyridin-2-
yl)ethyl)oxalamide (S5456), was  also found to inhibit CYP3A4 by
51% at 10 M using the same assay format (Senomyx, unpublished
results). However, neither compound signiﬁcantly inhibited any of
the CYP-isozymes (i.e., <50% inhibition at 10 M)  when retested on
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he same panel of CYP enzymes in the more deﬁnitive assay for-
at  utilizing human liver microsomes and CYP-speciﬁc substrates.
iven the low anticipated use levels of S3643 [1], this level of CYP
nhibition is not expected to interfere with normal metabolic pro-
esses. No other signiﬁcant off-target activities were seen in any of
he receptor proﬁling assays with 10 M of either S3643 or S5456.
The PK proﬁle of S3643 in male and female Sprague-Dawley
ats is very similar to that of the previous reported oxalamide
mami agonists S5456 and S336 (see Tables 3 and 9). S3643
as rapidly eliminated after intravenous administration in both
ale and female rats with mean terminal t1/2 of 0.19 and 0.16 h,
espectively. S5456 was also rapidly eliminated after intravenous
dministration of a 1.0 mg/kg bw dose with a mean terminal t1/2 of
.32 h in both male and female rats (Chi, unpublished results). Like-
ise, S336 at an intravenous dose of 0.1 mg/kg bw, was also rapidly
leared with a mean terminal t1/2 of 0.42 h in male rats [11].
The PK of S3643, S5456, and S336 has been studied at oral doses
f 10, 30, and 100 mg/kg bw.  The plasma t1/2 values for all three
ompounds tended to increase with increasing oral dose. For S3643,
1/2 ranged from 0.89 to 1.66 h in female rats and 0.80 to 1.66 h in
ale rats. The t1/2 values for S5456 ranged from 1.20 to 2.92 h in
emale rats and 0.95 to 1.35 h in male rats. Similar results were seen
ith S336 with t1/2 ranging from 0.69–0.98 h in male rats [11]. The
max of S3643 at the 100 mg/kg bw dose was 78.3 g/mL (238 M)
n male rats and 98.9 g/mL (310 M)  in females. The Cmax at the
00 mg/kg oral dose of S5456 was similar in both male and female
ats ranging from 33.1–34.7 g/mL (96.3–101 M);  the Cmax for
336 at this dose in male rats was 36.3 g/mL (106 M).
For all three compounds, AUClast increased in a greater than dose
roportional manner. This was particularly true for S5456 where a
0-fold increase in oral dose led to a 48.7-fold increase in AUClast
n female animals and an 18.6-fold increase in males. For S336,
hich was only studied in male rats, a 10-fold increase in oral dose
ed to 15.1-fold increase in AUClast. For S3643, a greater than dose
roportional increase was only seen in female animals where a 10-
old increase in oral dose led to a 16.8-fold increase in AUClast;
or males, a less than dose proportional increase (6.88-fold) was
bserved. With both S3643 and S5456, a greater than dose propor-
ional increase in mean AUC0–24 h was also seen in the TK studies
ssociated with the 90-day subchronic toxicity study with S3643
nd a 28-day subacute study conducted on S5456. As was  seen in
he single dose PK studies, the exposure of S5456 was signiﬁcantly
igher (2–3 fold) in female rats than in males on both Day 1 and
ay 28 (Senomyx, unpublished results).
The non-linear kinetics seen with oral doses of both S3643
nd the oxalamides is largely driven by a signiﬁcant decrease in
lasma clearance at higher doses which is indicative of saturation
f an elimination mechanism. It is not known whether this dose-
ependent decrease in intrinsic clearance is due to a saturation of
rst pass hepatic metabolism or saturation of some other elimina-
ion mechanism such as active renal transport. However, the larger
ncreases in AUC’s seen with S5456 and S3643 in female rats rela-
ive to males, suggests that the non-linear kinetics may  be due to
aturation of hepatic metabolism. Gender-dependent metabolism
f xenobiotics is a well-known phenomenon in rats that has been
ttributed to differences in the proﬁle of cytochrome P450 isozymes
ound in male and female rat liver [12,19]. It is possible one or
ore of the CYP enzymes involved in the metabolism of these com-
ounds is less abundant in female rats, and becomes saturated at
igher compound concentrations. If this metabolic pathway is rate-
imiting for the elimination of the compound, this could result in
igniﬁcantly lower intrinsic clearance and higher AUCs in female
ats versus males.
S3643 was evaluated for its genotoxic potential through a
tandard battery of in vitro genotoxicity assays which included
 bacterial reverse mutation assay (S. typhimurium strains TA98, Reports 3 (2016) 501–512
TA100, TA1535, TA1537 and E. coli strain WP2  uvrA), a chromo-
some aberration test in HPBL, and a micronucleus test in CHO-WBL
cells. S3643 was found to be neither mutagenic, clastogenic, nor
aneugenic in these in vitro genotoxicity assays. Oxalamide S5456
has also been shown to be non-mutagenic in a bacterial reverse
mutation assay using the same tester strains at concentrations up
to 5000 g/plate with and without metabolic activation (Senomyx,
unpublished results). In a plate incorporation assay, oxalamide
S336 was found to be weakly positive to TA1535 in the absence
of metabolic activation, and weakly positive to TA100 in a pre-
incubation assay in the presence of metabolic activation. However,
in neither case was  a dose response observed and S336 consis-
tently tested negative in the other tester strains under all conditions
at concentrations of up to 5000 g/plate. Given the lack of a
dose-dependent response and the fact that the mean number of
revertants was below historical spontaneous reversion or negative
control values, it was  concluded that S336 was non-mutagenic [5].
S336 was also found to be non-clastogenic in a chromosomal
aberration test in CHO-WBL cells in the presence and absence
of metabolic activation at concentrations up to 5000 g/mL [5].
S336 was  also evaluated for clastogenic activity and/or interfer-
ence with the spindle apparatus in an in vivo mouse micronucleus
assay. S336 was  administered by intraperitoneal (ip) injection to
male Swiss albino (CD-1) mice (21 animals/dose group) at doses
up to 800 mg/kg bw (maximum tolerated dose). At 24, 36, and 48 h
following dose administration, 7 animals from each group were
sacriﬁced, and their femoral bone marrow was harvested, ﬁxed and
stained. There were no statistically signiﬁcant differences observed
in the number of polychromatic erythrocytes with micronuclei or
reductions in the ratio of polychromatic erythrocytes to total ery-
throcytes between the S336 treated groups and the negative control
[5]. Overall, the results of the genotoxicity studies conducted on
S3643 and the oxalamide umami  agonists S5456 and S336 indicate
no safety concern for these substances with respect to genotoxicity.
The doses of S3643 selected for the 28- and 90-day toxicology
studies were designed to provide a high margin of safety rather than
deﬁne a maximum tolerated dose (MTD) in rats. Applying a 1000-
fold margin of exposure in extrapolating animal data to humans
to account for species differences in susceptibility, numerical dif-
ferences in population ranges between the test animals and the
human population, the greater variety of complicating disease pro-
cesses in the human population, and the possibility of synergistic
action among food additives, is believed to be an adequate margin
of safety for most substances proposed for use in food [4,16]. Based
on the anticipated annual volume of use (2000 kg), the per capita
intake (“eaters only”) of S3643 for use as a ﬂavour ingredient was
calculated to be 295 g/person/day (5 g/kg bw/day) [1]. There-
fore, based on the low anticipated use level of S3643, a NOAEL of
100 mg/kg bw/day in a sub-chronic toxicology study would provide
over a 20,000-fold margin of safety.
In the 90-day subchronic toxicology study with S3643, the mean
body weight of the female rats at 100 mg/kg bw/day was  statisti-
cally signiﬁcantly lower beginning at Week 5 (7% lower, p < 0.05)
when compared to controls which correlated with decreased mean
food consumption (6–14% lower, p < 0.05) throughout the dos-
ing period. There were no corresponding changes in mean body
weight or food consumption in the main study males at any dose
level. These effects were considered test article-related but not
adverse at these magnitudes. There were no test article-related
effects among clinical signs, ophthalmic examinations, hematol-
ogy parameters, coagulation times, clinical chemistry parameters,
or urinalysis parameters, or in the functional observation battery
in either sex at any dose level. Test article-related organ weight
changes consisted of increased liver weights in males at 100 mg/kg
bw/day relative to control animals which correlated to a minimal
degree of centrilobular hepatocyte hypertrophy. Centrilobular hep-
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Table  9
Pharmacokinetics of S5456 and S336 in Sprague-Dawley Rats.
Cmpd Route Dose (mg/kg bw) Sex Cmax (ng/mL) Tmax (h) t1/2 (h) AUC0-last (ng·h/mL) % F
S5456a iv 1.0 M 2633 ± 363 0.03 0.32 757 ± 112 –
F  2398 ± 391 0.03 0.32 817 ± 186 –
oral  gavage 10 M 3120 ± 787 0.25 0.95 3001 ± 498 39.6%
F  3258 ± 1087 0.25 1.20 4201 ± 1013 51.4%
30 M  7643 ± 2404 0.31 1.09 9535 ± 4190 42.0%
F  10980 ± 1500 0.33 1.59 26610 ± 7306 108.6%
100 M  33070 ± 14550 0.25 1.35 55950 ± 19820 73.9%
F  34670 ± 4196 0.92 2.92 204400 ± 44540 250.2%
S336b iv 0.1 M 207 ± 25.8 0.03 0.42 65.0 ± 1.3 –
oral  gavage 10 M 7027 ± 925 0.25 0.69 5809 ± 444 89.4%
30  M 23430 ± 1436 0.19 0.71 22260 ± 727 114.2%
100  M 36270 ± 6004 0.25 0.98 87490 ± 13350 134.6%
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Ca PK study of S5456 used 4 animals/sex for intravenous dosing, and 3 animals/sex
b PK study of S336 used 4 male rats for intravenous dosing, and 3 male rats/group
tocyte hypertrophy is usually representative of enzyme induction,
hich is considered an adaptive response [9] and therefore not
onsidered to be adverse. The 90-day subchronic toxicity study
stablished a NOAEL for S3643 of 100 mg/kg bw/day (the highest
ose evaluated), for both male and female Sprague-Dawley rats.
The potential for in vivo toxicity of two of the structurally related
xalamide umami  agonists has also been evaluated in rats. The
oxicity of S5456 was studied in male and female Crl:CD (SD) rats
10 animals/sex/group) at doses up to 140 mg/kg bw/day adminis-
ered as a suspension in 1% MC  by oral gavage for 28 days. Similarly,
he toxicity of S336 was evaluated in male and female Crl:CD (SD)
GS BR rats (20 animals/sex/group) via feeding in the diet at nom-
nal doses up to 100 mg/kg bw/day for 92 or 93 days. With both
5456 and S336, there were no test article-related effects among
linical signs, body weights, ophthalmic examinations, hematol-
gy parameters, coagulation times, clinical chemistry parameters,
r urinalysis parameters, or in the functional observation battery
n either sex at any dose level. There were no test article-related
rgan weight, macroscopic or microscopic changes in the tissues
xamined noted at any dose level. The 28-day short term toxicity
tudy established a NOEL for S5456 of 140 mg/kg bw/day (the high-
st dose evaluated), for both male and female Sprague-Dawley rats
Senomyx, unpublished results). Likewise, the NOEL in rats admin-
stered S336 in diet for 92 or 93 days was at least 100 mg/kg bw/day
5].
According to the Maximized Survey-derived Daily Intake (MSDI)
pproach, the margin of safety for S336 based on the estimated
aily per capita intake of this substance in both Europe and the
SA was viewed to be adequate and it was not anticipated to pose
 safety concern when used as a ﬂavouring substance at the esti-
ated levels of intake [5]. Based on a daily per capita intake estimate
f 295 g/person/day [1] and its NOAEL in the 90-day subchronic
oxicity study in rats, S3643 is also believed not to pose a safety
azard when used as a ﬂavouring substance.
In conclusion, S3643 demonstrated a lack of genotoxicity with or
ithout metabolic activation in vitro at concentrations that greatly
xceed those observed in rat plasma following oral administration
f S3643 at doses up 100 mg/kg bw.  The results of a 90-day sub-
hronic toxicity study established NOAEL for S3643 of 100 mg/kg
w/day (the highest dose evaluated), for male and female rats.
ssuming that the systemic exposure of S3643 after oral adminis-
ration to humans is comparable to that observed at an equivalent
ose in the rat, this NOAEL is several orders of magnitude higher
han the anticipated human exposure for S3643 under the condi-
ions of intended use [1].onﬂict of interest
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